Drug intelligence / Profile preview

human papillomavirus vaccine types 16 and 18 + hepatitis a and hepatitis b vaccine

Development stage: Unknown
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

Cervarix + Twinrix Paediatric refers to the co-administration of two distinct vaccines developed by GSK: Cervarix, a bivalent vaccine targeting Human Papillomavirus (HPV) types 16 and 18, and Twinrix Paediatric, a combination vaccine for Hepatitis A and Hepatitis B. Cervarix utilizes recombinant L1 proteins that self-assemble into virus-like particles (VLPs) and is formulated with the AS04 adjuvant system, which includes monophosphoryl lipid A (MPL) and aluminum hydroxide. Twinrix Paediatric contains inactivated Hepatitis A virus and recombinant Hepatitis B surface antigen (HBsAg) adsorbed onto aluminum salts. This combination is typically evaluated in clinical settings to assess the immunogenicity and safety of simultaneous vaccination against HPV, HAV, and HBV in pediatric or adolescent populations, ensuring that co-administration does not interfere with the immune response to the individual components.

Other names: HPV 16/18 + HAV/HBV vaccine co-administrationCervarix + Twinrix Paediatric

Targets

HBsAg (Hepatitis B surface antigen)HPV16 (Human papillomavirus type 16)HPV18 L1

Beyond the preview

Go deeper on human papillomavirus vaccine types 16 and 18 + hepatitis a and hepatitis b vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on human papillomavirus vaccine types 16 and 18 + hepatitis a and hepatitis b vaccine.